Weak Trigger
now
Monoclonal antibody 'Rocatinlimab' for moderate-to-severe atopic dermatitis delivers surprise Phase 2 results, showing 75% skin clearance in trial subjects.
24h Trigger History
No history available
No trigger updates found for this ticker in the last 24 hours.
| Advertisement |